Showing results (231-240 of 249) with videos related to

Sort By:
Pageof 25
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Tumori|June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-SMaria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burdenLeonardo Provenzano, Yong Xiang Gwee, Veronica Conca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.
The Oncologist|March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selectionLetizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.
The Oncologist|August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumorsFrancesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Annals of Surgical Oncology|April 11, 2024
Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic ReviewBas A Uijterwijk, Daniël H Lemmers, Giuseppe Kito Fusai, et al.
Pageof 25